Connect with us

Fetzima (levomilnacipran)

Levomilnacipran (or FETZIMA®) is mainly prescribed to treat major depressive disorder.

Status: ACTIVE

Class: Serotonin-norepinephrine Reuptake Inhibitor (SNRI)

FDA Approval: 2013

Dosage Forms: 20 mg, 40 mg, 80 mg, 120 mg

Biological Half-life: 12 hours

Side Effects: Dizziness, nausea, sweating, constipation, insomnia, high blood pressure, tachycardia, urinary hesitancy, erectile dysfunction

Routes of Administration: Oral

Pregnancy Category: C (US)


© 2018 Mental Daily. All Rights Reserved.
Our content is for informational purposes and should not be used as medical or treatment recommendation.